Comparative Study of Levonadifloxacin (IV and Oral) With Linezolid (IV and Oral) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

• Status: Completed
• Trial end date: 2018-11-30
• Target enrollment: 0
• Participant gender: All

Summary

This is a phase III, multi-center, randomized, active-comparator, study in subjects with ABSSSI. The study has two subgroups for assessment of efficacy and safety - oral subgroup 1 and IV subgroup 2. Each subgroup will comprise of two treatment arms.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wockhardt
• Treatments: Levonadifloxacin; Linezolid

Criteria

Inclusion Criteria:

• Subjects must be willing to participate in the study and provide a written informed consent

• Subjects with ABSSSI characterized by any of the following infection types:

1. Cellulitis/erysipelas: diffuse skin infection characterized by spreading areas of redness, edema, and/or induration

2. Wound infection: An infection characterized by purulent drainage from a wound with surrounding redness, edema, and/or induration

3. Major cutaneous abscess: An infection characterized by a collection of pus within the dermis or deeper that is accompanied by redness, edema, and/or induration

• Subjects with lesion size area of at-least 75 cm2. Lesion size will be measured by the area of redness, edema, or induration

• Subjects with suspected and/or documented evidence of Gram-positive infection

Exclusion Criteria:

• 1. ABSSSI meeting any of the following criteria:

1. Severely impaired arterial blood supply (such that the likelihood of amputation of the infected anatomical site is likely)

2. ABSSSI expected to require more than 10 days of antimicrobial therapy as per the discretion of the Investigator

3. Subject with suspected or confirmed osteomyelitis or septic arthritis or gangrene

4. ABSSSI requiring surgical intervention (except surgical incision and drainage for abscess) 2. Subjects who have received prior antibiotic therapy within past 24 hours for the treatment of current episode of ABSSSI. Following are the exceptions to this criteria:

1. Subjects who received a single dose of a short-acting antibacterial drug within 24 hours of enrolment

2. Subjects with evidence of clinical progression of ABSSSI while on antibacterial drug therapy after at-least 48 hours

3. Subjects who received an antibacterial drug for surgical prophylaxis and subsequently develop ABSSSI 3. Subjects with current history or diagnosis of HIV, positive test result for hepatitis B surface antigen (HBsAg) or Hepatitis C virus (HCV) 4. Subjects with any clinically significant abnormalities in pulmonary, gastrointestinal, endocrine, hepatic or renal systems